Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1800 • ACR Convergence 2021
Altered Metabolic Profiles in the Transition from Psoriasis to Psoriatic Arthritis: A Longitudinal Analysis
Ananta Paine¹, Paul Brookes², Dongmei Li³, Somyaroop Bhattacharya⁴, Maria de la Luz Garcia-Hernandez¹ and Christopher Ritchlin¹, ¹Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ²Department of Pharmacology & Physiology, University of Rochester Medical Center, Rochester, NY, ³Department of Clinical and Translational Research, University of Rochester Medical Center, Rochester, NY, ⁴Division of Neonatology, Department of Pediatrics, University of Rochester, Rochester, NY
Background/Purpose: The transition to psoriatic arthritis (PsA) occurs in 20-30% of psoriasis (Ps) patients, but the mechanisms underlying the emergence of musculoskeletal disease are not…
Abstract Number: 1818 • ACR Convergence 2021
Real-World Efficacy of TNF Inhibitors for Treatment of Psoriatic Arthritis by Disease Domains: 6-Month Findings from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip Mease¹, Taylor Blachley², Jacqueline O’Brien², Nicole Middaugh², Greg Kricorian³, Scott Stryker³, David Collier⁴ and Alexis Ogdie-Beatty⁵, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³Amgen Inc., Thousand Oaks, CA, ⁴Amgen Inc., Simi Valley, CA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: The burden of PsA and its chronic symptoms may have considerable impact on patient function and quality of life. Real-world research is limited on…
Abstract Number: 1920 • ACR Convergence 2021
Association of C-reactive Protein and Non-Steroidal Anti-inflammatory Drugs with Cardiovascular Events in Patients with Psoriatic Arthritis: A Time-dependent Cox Regression Analysis
Ho Man Lam¹, Ho So², Isaac Cheng¹, Edmund Li¹, Priscilla Wong³, Tena Li¹, Alex Lee¹ and Lai-Shan Tam⁴, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²CUHK, Hong Kong, China, ³Prince of Wales Hospital, Hong Kong, Hong Kong, ⁴Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)
Background/Purpose: Psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to underlying inflammation. Whether inflammatory burden and drugs used to suppress inflammation over time are…
Abstract Number: 0060 • ACR Convergence 2021
Lipidomic Profiling Identifies Different Expression of Oxylipins Between Synovial Tissue and Plasma of Patients with Rheumatoid and Psoriatic Arthritis
Abha Singh¹, Jessica Murillo Saich², Roxana Coras³, Julio Ramirez⁴, Eric Chang², Raquel Celis⁵, Aaron Armando², Oswald Quehenberger², Arthur Kavanaugh², Juan D Cañete⁶ and Monica Guma⁷, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA, ³University of California San Diego/Department of Medicine, Autonomous University of Barcelona, San Diego, CA, ⁴Arthritis Unit, Rheumatology Department, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁵Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁶Rheumatology Department, Hospital Clinic, Barcelona, Spain, ⁷University of California San Diego/San Diego VA Healthcare Service/Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Oxylipins are bioactive lipids derived from polyunsaturated fatty acids (PUFAs) that modulate inflammation. Oxylipins derived from n-6 PUFA precursors, such as arachidonic acid (AA),…
Abstract Number: 0449 • ACR Convergence 2021
Identification of Serum Protein Biomarkers at Baseline to Distinguish Radiographic Progressors from Non-Progressors in Patients with Active Psoriatic Arthritis
Orla Coleman¹, Bruna Wundervald², Ruoyi Zhou³, James Waddington³, Robert LJ Graham⁴, Ciaren Graham⁴, Geoff McMullan⁴, Andrew C. Parnell⁵, Vinod Chandran⁶, Philip Mease⁷, Gaia Gallo⁸, Venkatesh Krishnan⁸, Stephen Pennington⁹ and Oliver FitzGerald¹⁰, ¹Atturos, Bray, Ireland, ²Atturos, Maynooth, Ireland, ³Atturos, Belfield, Ireland, ⁴Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom, ⁵Maynooth University, Maynooth, Ireland, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹University College Dublin, Dublin, Ireland, ¹⁰Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland
Background/Purpose: A delay in diagnosis and management of patients with PsA leads to poor radiographic and functional outcomes [1]. The need to identify which patients…
Abstract Number: 0805 • ACR Convergence 2021
A Real-world Prospective Observational Study of the Effectiveness of Golimumab in Adult Greek Patients with RA, PsA and Axial SpA and Inadequate Response to Initial TNFα Inhibitor Therapy
Panagiotis Athanassiou¹, Dimitrios Psaltis², Athanasios Georgiadis³, Gkikas Katsifis⁴, Athina Theodoridou⁵, Souzana Gazi⁶, Prodromos Sidiropoulos⁷, Maria Tektonidou⁸, Andreas Bounas⁹, Anna Kandyli¹⁰, Periklis Vounotrypidis⁵, Grigorios Sakellariou⁵, Dimitrios Vassilopoulos¹¹, Zhiping Huang¹², Evangelia Petrikkou¹³ and Dimitrios Boumpas¹⁴, ¹Department of Rheumatology, St. Paul’s Hospital of Thessaloniki, Thessaloniki, Greece, ²Private Practice, Serres, Greece, Athens, Greece, ³Private Practice, Ioannina, Greece, Athens, Greece, ⁴Rheumatology Clinic Naval Hospital of Athens, Athens, Greece, ⁵Private Practice, Thessaloniki, Greece, Athens, Greece, ⁶“KAT” Regional General Hospital, Rheumatology Unit, Athens, Greece, Athens, Greece, ⁷Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Greece, ⁸Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Joint Rheumatology Program, Laiko Hospital, Athens, Greece, ⁹General Clinic of Patras “Olympion”, Rheumatology, Patras, Greece, ¹⁰Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece, ¹¹2nd University Department of Internal Medicine, General Hospital of Athens "Ippokrateion", Athens, Greece, ¹²Merck & Co., Inc., Pharmacoepidemiology, Center for Observational and Real-world Evidence (CORE), Kenilworth, NJ, ¹³MSD Pharmaceutical, Industrial and Commercial S.A, Athens, Medical Affairs, Athens, Greece, ¹⁴Rheumatology and Clinical Immunology, 4th Department of Internal Medicine, ‘‘Attikon’’ University Hospital, Athens, Greece
Background/Purpose: Patients (pts) with immune-mediated rheumatic diseases and an insufficient response to previous treatment with TNFα inhibitors (TNFαi) are frequently encountered in clinical practice. This…
Abstract Number: 1220 • ACR Convergence 2021
Identification of Underlying Disease Domains by Longitudinal Latent Factor Analysis for Secukinumab Treated Patients in Psoriatic Arthritis and Rheumatoid Arthritis Trials
Xuan Zhu¹, Fabian Falck², Sahra Ghalebikesabi², Matthias Kormaksson¹, Marc Vandemeulebroecke³, Cong Zhang¹, Luis Santos⁴, Chun Hei Kwok⁴, Dominique West⁴, Ann-Marie Mallon⁴, Ruvie Martin¹, Aimee Readie¹, Kunal Gandhi¹, Gregory Ligozio¹ and George Nicholson², ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²University of Oxford, Oxford, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴MRC Harwell Institute, Harwell Campus, Oxfordshire, United Kingdom
Background/Purpose: Secukinumab is a fully monoclonal antibody approved for the treatment of several related autoinflammatory diseases, including psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis.1 While…
Abstract Number: 1333 • ACR Convergence 2021
Guselkumab (TREMFYA®) Provides Consistent and Durable Pain Improvement in Patients with Active Psoriatic Arthritis: Results of 2 Phase 3, Randomized, Controlled Clinical Trials
Peter Nash¹, Lai-Shan Tam², Wen-Chan Tsai³, Ying-Ying Leung⁴, Daniel Furtner⁵, Shihong Sheng⁶, Yanli Wang⁶, May Shawi⁷, Alexa Kollmeier⁸, Jonathan Sherlock⁹ and Daniel Cua⁶, ¹Griffith University, Brisbane, Australia, ²Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic), ³Janssen Research & Development, LLC, Kaohsiung City, Taiwan (Republic of China), ⁴Singapore General Hospital and Duke-NUS Medical School, Singapore, Singapore, ⁵Janssen, a division of Johnson & Johnson Pte. Ltd., Singapore, Singapore, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Research & Development, LLC and University of Oxford, Spring House, PA
Background/Purpose: Guselkumab (GUS), a targeted inhibitor of IL-23p19, demonstrated significant efficacy v placebo (PBO) in achieving ACR20 response at week (W) 24 in patients (pts)…
Abstract Number: 1350 • ACR Convergence 2021
Sustained Improvement in Physical Function, Disease Impact and Health-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Bimekizumab: 3-Year Results from a Phase 2b Open-Label Extension Study
Laure Gossec¹, Akihiko Asahina², Alice Gottlieb³, Laura Coates⁴, Barbara Ink⁵, Deepak Assudani⁶, Jason Coarse⁷, Scarlett Hellot⁸, Jason Eells⁶ and Philip Mease⁹, ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁵UCB Celltech, Slough, UK, Slough, United Kingdom, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Colombes, France, ⁹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17F and IL-17A, and has demonstrated clinical improvements in joint and skin…
Abstract Number: 1532 • ACR Convergence 2021
Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease
Rebecca Haberman¹, Ramin Herati¹, David Simon², marie Samanovic¹, Michael Tuen¹, Rebecca Blank³, Sergei Koralov¹, Raja Atreya⁴, Koray Tascilar⁵, Joseph Allen¹, Rochelle Castillo⁶, Amber Cornelius¹, Paula Rackoff³, Gary Solomon⁷, Samrachana Adhikari¹, Natalie Azar⁸, Pamela Rosenthal⁹, Peter Izmirly¹⁰, Jonathan Samuels¹¹, Brian Golden¹², Soumya Reddy⁹, Markus Neurath⁴, Steven B. Abramson¹⁰, Georg Schett¹³, Mark Mulligan¹ and Jose Scher¹⁰, ¹NYU Grossman School of Medicine, New York, NY, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nrnberg, Erlangen, Germany, ³New York University, New York, NY, ⁴Deutsches Zentrum fur Immuntherapie, FAU Erlangen-Nuremberg and Universitatsklinikum Erlangen, Erlangen, Germany, ⁵Friedrich Alexander University of Erlangen Nuremberg, Universitaetsklinikum Erlangen Department of Medicine-3 Rheumatology and Immunology, Erlangen, Germany, ⁶NYU Langone Health, New York, NY, ⁷NYU Langone School of Medicine, Hartsdale, NY, ⁸NYU Langone, New York, NY, ⁹NYU School of Medicine, New York, NY, ¹⁰New York University School of Medicine, New York, NY, ¹¹NYU Langone, Rye Brook, NY, ¹²NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY, ¹³Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Patients with immune mediated inflammatory disorders (IMIDs) have an inherently heightened susceptibility to infection and may be considered high risk for developing COVID-19. While…
Abstract Number: 1785 • ACR Convergence 2021
Prevalence and Incidence of PsA in Germany – a Cohort Study with 65 Million Participants
Madeline Denke¹, Matthias Schneider², Ralph Brinks¹ and Philipp Sewerin³, ¹Department for Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ²Policlinic & Hiller Research Unit Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany, ³Department and Hiller Research Unit of Rheumatology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
Background/Purpose: Patients suffering from Psoriatic-Arthritis (PsA) can experience a substantial burden of disease, which may result in a significant reduction of their quality of life.…
Abstract Number: 1801 • ACR Convergence 2021
The Effect of Ixekizumab versus Adalimumab on Individual Components of the ACR Composite Score, with and Without Concomitant Methotrexate or Other Conventional Synthetic DMARDs at 52 Weeks in Patients with Psoriatic Arthritis
Elaine Husni¹, Sona Kamat², Keri Stenger³, Rebecca Bolce³, Thorsten Holzkaemper⁴, Cameron Helt³, So Young Park³, Jeffrey Lisse⁵ and Luca Idolazzi⁶, ¹Cleveland Clinic, Cleveland, OH, ²St Louis University, Saint Louis, MO, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Bad Homburg, Germany, ⁵Eli Lilly and Company, Tucson, AZ, ⁶University of Verona, Verona, Italy
Background/Purpose: It is important to understand how to select among the multiple treatment options for active psoriatic arthritis (PsA). Since individual patient domains may influence…
Abstract Number: 1819 • ACR Convergence 2021
Tildrakizumab Efficacy and Safety in Patients with Psoriatic Arthritis by Metabolic Syndrome Status
Arthur Kavanaugh¹, Siba Raychaudhuri², Christopher Ritchlin³, Akihiko Asahina⁴, Proton Rahman⁵, Fred Murphy⁶, Stephen Rozzo⁷, Siu-Long Yao⁷, Richard C Chou⁸ and Elaine Husni⁹, ¹Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, Sacramento, CA, ³Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁴Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ⁵Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁸University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, Buffalo, NY, ⁹Cleveland Clinic, Cleveland, OH
Background/Purpose: Metabolic syndrome (MetS) is a combination of specific risk factors for cardiovascular disease.1 The prevalence of MetS in patients (pts) with PsA has been…
Abstract Number: 1921 • ACR Convergence 2021
Axial Psoriatic Arthritis: Correlation Between Whole Spine MRI Abnormalities and Clinical Findings
Pamela Diaz¹, Iris Eshed², Joy Feld³ and Lihi Eder¹, ¹University of Toronto, Toronto, ON, Canada, ²Sheba Medical Center, Ramat Gan, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel
Background/Purpose: Psoriatic Arthritis (PsA) typically affects peripheral joints, but in some patients the disease can involve the spine. While magnetic resonance imaging (MRI) is an…
Abstract Number: 0061 • ACR Convergence 2021
Harnessing Spatially-Resolved Gene Expression to Characterize the Transcriptional Landscape of Psoriatic Skin
Rochelle Castillo¹, Ikjot Sidhu¹, Di Yan¹, Piotr Konieczny¹, Rebecca Haberman¹, Brandon Hsieh¹, Andrea Neimann¹, Shruti Naik¹ and Jose Scher², ¹NYU Langone Health, New York, NY, ²New York University School of Medicine, New York, NY
Background/Purpose: The skin is recognized as a window into the immunopathogenic mechanisms in the psoriatic arthritis (PsA) joint. This is evidenced by the fact that…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].